Addex Therapeutics Ltd Financials
This page shows Addex Therapeutics Ltd (ADXN) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. All figures are derived from SEC filings (10-K and 10-Q reports).
FY2025 shows a small-revenue footprint spread across a very large share base, pointing to an early-stage operating profile.
FY2025 revenue was only$5.0M while shares outstanding were 147.8M. That works out to about$34K of annual revenue per 1M shares, suggesting a business still defined more by capital structure than by scaled commercial activity.
Because the filing does not provide cash flow, assets, or liabilities here, the key unanswered question is funding mechanics: whether this revenue can support operations internally or whether the business still relies mainly on external financing.
Some figures from recent filings were inconsistent and were omitted from this summary.
Key Financial Metrics
Earnings & Revenue
Addex Therapeutics Ltd generated $5.0M in revenue in fiscal year 2025.
Cash & Balance Sheet
Addex Therapeutics Ltd had 148M shares outstanding in fiscal year 2025.
Margins & Returns
Capital Allocation
ADXN Income Statement
Similar Companies
Frequently Asked Questions
What is Addex Therapeutics Ltd's annual revenue?
Addex Therapeutics Ltd (ADXN) reported $5.0M in total revenue for fiscal year 2025. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.